Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: A multicenter, randomized trial

Transplantation

Volumn 89, Issue 7, 2010, Pages 864-872

  Gullestad, Lars ^a   Iversen, Martin ^b   Mortensen, Svend Aage ^b   Eiskjær, Hans ^c   Riise, Gerdt C ^d   Mared, Lena ^e   Bjørtuft, Oystein ^f   Ekmehag, Björn ^e   Jansson, Kjell ^g   Simonsen, Svein ^f   Gude, Einar ^f   Rundqvist, Bengt ^d   Fagertun, Hans E ^h   Solbu, Dag ⁱ   Bergh, Claes Håkan ^d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^h Capturo AS (Statistics) Kjeller   (Norway)

ⁱ Medical Department   (Norway)

Author keywords

Certican; CNI; Cyclosporine; Everolimus; Renal Impairment; Tacrolimus

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ADULT; ARTHRITIS; ARTICLE; BONE MARROW TOXICITY; BREAST ABSCESS; BRONCHIOLITIS OBLITERANS; CLINICAL TRIAL; COHORT ANALYSIS; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; GOUT; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEADACHE; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEG EDEMA; LEUKOPENIA; LUNG ALVEOLUS PROTEINOSIS; LUNG EMBOLISM; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; MUSCLE ATROPHY; MYALGIA; NAUSEA; NEOPLASM; NEPHROTOXICITY; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SHIVERING; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; THROMBOEMBOLISM; VOMITING; WEIGHT REDUCTION;

AGED; CALCINEURIN; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; SCANDINAVIA; SIROLIMUS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950952997     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181cbac2d     Document Type: Article

References (33)

1. Zuckermann AO, Aliabadi AZ. Calcineurin-inhibitor minimization protocols in heart transplantation. Transpl Int 2009; 22: 78.
2. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant 2004; 23(suppl 5): S202.
3. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Eng J Med 2003; 349: 931.
4. Mehra MR. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 2006; 6: 1248.
5. Taylor DO, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report\2008. J Heart Lung Transplant 2008; 27: 943.
6. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.
7. Bohler T, Waiser J, Budde K, et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 1998; 30: 2195.
8. Zuckermann A, Manito N, Epailly E, et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008; 27: 141.
9. Snell GI, Westall GP. Immunosuppression for lung transplantation: evidence to date. Drugs 2007; 67: 1531.
10. Schuurman H-J, Pally C, Weckbecker G, et al. SDZ RAD inhibits cold ischemia-induced vascular remodeling.Transplant Proc1999; 31: 1024.
11. Eisen HJ, Tuzcu EM, Dorent R, et al. RAD B253 Study Group. Everoli-mus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
12. Snell GI, Valentine VG, Vitulo P, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006; 6: 169.
13. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234.
14. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
15. Ekberg H. Calcineurin inhibitor sparing in renal transplantation. Transplantation 2008; 86: 761.
16. Gonzá lez-Vílchez F, de Prada JA, Exposito V, et al. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. J Heart Lung Transplant 2008; 27: 1135.
17. Rothenburger M, Teerling E, Bruch C, et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 2007; 26: 305.
18. Sánchez-Brotons JA, Sobrino-Márquez JM, Lage-Gallé E, et al. Preliminary experience with conversion from calcineurin inhibitors to everolimus in cardiac transplantation maintenance therapy. Transplant Proc 2008; 40: 3046.
19. Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21: 540.
20. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77: 568.
21. Ross H, Pflugfelder P, Haddad H, et al. CADENCE Study Group. Cy-closporine reductionin the presence ofeverolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. J Heart Lung Transplant 2008; 27: 197.
22. Schweiger M, Wasler A, Prenner G, et al. Everolimus and reduced cy-closporine trough levels in maintenance heart transplant patients. Transpl Immunol 2006; 16: 46.
23. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporineonthe pharmacokineticsofmycophenolic acid. Ther Drug Monit 2001; 23: 119.
24. Kaplan B, Meier-Kriesche H-U, Minnick P, et al. Randomized cal-cineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant 2005; 19: 551.
25. Poggio ED, Wang X, Weinstein DM, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006; 6: 100.
26. Miller MR, Hankinson J, Brusasco V, et al. ATS/ERS Task Force. Standardisation of spirometry. Europ Respir J 2005; 26: 319.
27. Montgomery DC. Design and analysis of experiments [ed. 2]. New York, Wiley 1984.
28. Nankivell BJ, Borrows RJ, Fung CL-S,et al. Calcineurin inhibitor neph-rotoxicity: longitudinal assessmentbyprotocol histology. Transplantation 2004; 78: 557.
29. Groetzner J, Kaczmarek I, Schulz U, et al. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 2009; 87: 726.
30. Iversen M, Nilsson F, Sipponen J, et al. Ciclosporine C2 levels have impact on rejection incidence in de novo lung, but not in heart transplant recipients. Results from the Nordic "NOCTURNE" study. J Heart Lung Transplant (in press).
31. Ross H, Pflugfelder P, Haddad H, et al. Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study. Transplant Int (in press).
32. Arora S, Andreassen A, Simonsen S, et al. Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy. Transplantation 2007; 84: 149.
33. Burton CM, Carlsen J, Mortensen J, et al. Long term survival after lung transplantation depends on the development and severity of bronchi-olitis obliterans syndrome. J Heart Lung Transplant 2007; 26: 681.